<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00687674</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000597065</org_study_id>
    <secondary_id>P30CA015083</secondary_id>
    <secondary_id>MC078A</secondary_id>
    <secondary_id>07-006234</secondary_id>
    <secondary_id>NCI-2009-01284</secondary_id>
    <secondary_id>RV-MM-PI-0142</secondary_id>
    <secondary_id>SR06-933</secondary_id>
    <nct_id>NCT00687674</nct_id>
  </id_info>
  <brief_title>Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma</brief_title>
  <official_title>Phase I/II Study of Sorafenib, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Sorafenib may stop the growth of cancer cells by blocking some of the enzymes
      needed for cell growth. Lenalidomide may stimulate the immune system in different ways and
      stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in
      different ways to stop the growth of cancer cells, either by killing the cells or by stopping
      them from dividing. Sorafenib and lenalidomide may also stop the growth of cancer cells by
      blocking blood flow to the cancer. Giving sorafenib together with lenalidomide and
      dexamethasone may kill more cancer cells.

      PURPOSE: This phase I/II trial is studying the side effects and best dose of sorafenib when
      given together with lenalidomide and dexamethasone and to see how well they work in treating
      patients with relapsed or refractory multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  To determine the maximum tolerated dose of sorafenib tosylate and lenalidomide in
           combination with dexamethasone in patients with relapsed or refractory multiple myeloma.
           (phase I)

        -  To describe the toxicity of this regimen in these patients. (phase I)

        -  To evaluate the confirmed response in patients treated with this regimen. (phase II)

      Secondary

        -  To correlate clinical effects (adverse events and/or tumor response or activity) with
           pharmacologic parameters (pharmacokinetics or pharmacodynamics) and/or biologic results
           (correlative laboratory). (phase II)

        -  To assess overall survival and time to disease progression in patients treated with this
           regimen. (phase II)

      OUTLINE: This is a phase I, dose-escalation study of sorafenib tosylate in combination with
      lenalidomide followed by a phase II study.

      Patients receive oral sorafenib tosylate once to twice daily on days 1-28, oral lenalidomide
      once daily on days 1-21, and oral dexamethasone on days 1, 8, 15, and 22. Treatment repeats
      every 28 days in the absence of disease progression or unacceptable toxicity.

      Patients undergo blood and bone marrow sample collection periodically during study for
      laboratory correlative studies. Bone marrow plasma samples (i.e., fresh marrow aspirates) are
      assessed for marrow angiogenesis (microvessel density) by IHC; angiogenic capability (tubular
      network formation) by in vitro angiogenesis assay; tumor cell proliferation by
      bromo-2-deoxyuridine uptake; tumor cell apoptosis by three-color flow cytometry (CD38, CD45
      or CD138, and 7AAD); and expression of VEGF and soluble VEGF receptors on plasma cells by
      enzyme-linked immunosorbent assay. Bone marrow biopsies are assessed for various
      phosphoproteins by IHC; phosphorylation status of ERK1/2 by immunoblotting; and for
      pharmacodynamic markers (e.g., P70 S6K) by immunoblotting. Blood samples are assessed for
      surface markers of circulating endothelial cells (CD105, CD34, and CD146) by flow cytometry
      and for circulating endothelial cell progenitors by late colony formation in mononuclear
      cells. The endothelial lineage is confirmed by phenotyping of surface markers for endothelial
      cells.

      After completion of study therapy, patients are followed periodically for up to 3 years.

      PROJECTED ACCRUAL: A total of 39 patients will be accrued for phase I and 44 for phase II of
      this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to study design (and toxicity), this trial closed to accrual prior to opening the phase II
    portion.
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Grade 3 and 4 Adverse Event (Phase I)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.
Description of Grades:
Grade 1: Mild Grade 2: Moderate Grade 3: Severe Grade 4: Life-threatening Grade 5: Death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Achieve a Confirmed Response (Partial Response [PR], Very Good PR [VGPR], Complete Response [CR], or Stringent CR [sCR]) (Phase II)</measure>
    <time_frame>Duration on Treatment (up to 3 years)</time_frame>
    <description>Response that was confirmed on 2 consecutive evaluations during treatment
CR: Complete disappearance of M-protein from serum &amp; urine on immunofixation, &lt;5% plasma cells in bone marrow (BM)
sCR: CR plus normal FLC ratio &amp; absence of clonal cells in BM
VGPR: &gt;=90% reduction in serum M-component; Urine M-Component &lt;100 mg per 24 hours; &lt;=5% plasma cells in BM
PR: &gt;= 50% reduction in serum M-Component and/or Urine M-Component &gt;= 90% reduction or &lt;200 mg per 24 hours; or &gt;= 50% decrease in difference between involved and uninvolved FLC levels</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (Phase II)</measure>
    <time_frame>From registration to death (up to 3 years)</time_frame>
    <description>Overall Survival (OS) was defined as the time from registration to death of any cause. Participants were followed for a maximum of 2 years from registration. The median OS with 95%CI was estimated using the Kaplan Meier method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression (Phase II)</measure>
    <time_frame>From registration to progression (up to 3 years)</time_frame>
    <description>Time to disease progression (TTP) was defined as the time from registration to progression. The median TTP with 95%CI was estimated using the Kaplan Meier method.
Progression was defined as any one or more of the following:
An increase of 25% from lowest confirmed response in:
Serum M-component (absolute increase &gt;= 0.5g/dl)
Urine M-component (absolute increase &gt;= 200mg/24hour
Difference between involved and uninvolved Free Light Chain levels (absolute increase &gt;= 10mg/dl
Bone marrow plasma cell percentage (absolute increase of &gt;=10%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Microvessel Density From Baseline to Post-treatment and Correlation With &gt; Clinical Outcomes (Phase II)</measure>
    <time_frame>Pre and Post treatment (up to 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Apoptosis Rate From Baseline to Post-treatment and Correlation With &gt; Clinical Outcomes (Phase II)</measure>
    <time_frame>Pre and Post treatment (up to 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Cell Gene Expression Profiles and Correlation With &gt; Clinical Outcomes</measure>
    <time_frame>Post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Stained Circulating Endothelial Cells and Endothelial Progenitor Cells and Correlation With Clinical Outcomes (Phase II</measure>
    <time_frame>Post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in VEGF Expression Levels and Correlation With Clinical Outcomes (Phase II)</measure>
    <time_frame>Post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Sorafenib + Lenalidomide + Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>20 mg orally Days 1, 8, 15, 22 of 28 day cycle</description>
    <arm_group_label>Sorafenib + Lenalidomide + Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sorafenib tosylate</intervention_name>
    <description>Phase I - dose escalating: 200mg once daily dose level -2, 200mg once daily dose level -1, 200mg once daily dose level 0, 200mg twice daily dose level 1, 200mg twice daily dose level 2, 400mg AM &amp; 200mg PM daily dose level 2a, 400mg twice daily dose level 3 orally days 1-28 every 28 days until progression</description>
    <arm_group_label>Sorafenib + Lenalidomide + Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Phase I - dose escalating: 5mg level -2, 10mg level -1, 15mg level 0, 15mg level 1, 25mg level 2, 25mg level 2a, 25mg level 3 orally days 1-21 every 28 days until progression</description>
    <arm_group_label>Sorafenib + Lenalidomide + Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of multiple myeloma

               -  Relapsed or refractory disease requiring treatment

          -  Measurable disease, as defined by at least 1 of the following:

               -  Serum monoclonal protein ≥ 1.0 g

               -  More than 200 mg of monoclonal protein in the urine on 24-hour electrophoresis

               -  Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum
                  immunoglobulin kappa to lambda free light chain ratio

               -  Monoclonal bone marrow plasmacytosis ≥ 30% (i.e., evaluable disease)

          -  No known standard therapy that is potentially curative for the patient's disease

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Life expectancy ≥ 12 weeks

          -  ANC ≥ 1,000/μL

          -  Platelet count ≥ 75,000/μL

          -  Hemoglobin ≥ 9 g/dL

          -  Direct bilirubin ≤ 1.5 times upper limit of normal (ULN)

          -  AST ≤ 3 times ULN (≤ 5 times ULN if the liver is involved)

          -  Creatinine ≤ 2.5 times ULN

          -  Patients with treated or untreated POEMS (Patient-Oriented Evidence That Matters)
             allowed, provided they satisfy the criteria for measurable disease

          -  No other prior malignancy within the past year except currently treated basal cell or
             squamous cell skin cancer, carcinoma in situ of the cervix or breast, or prostate
             cancer not requiring therapy

          -  No other active malignancy requiring treatment that would interfere with the
             assessments of response of the myeloma to protocol treatment

          -  INR &lt; 1.5 OR PT/PTT ≤ 1.5 times ULN

               -  Patients receiving anticoagulation treatment with an agent such as warfarin or
                  heparin are allowed

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use 2 methods of effective contraception for 28 days prior,
             during, and for 28 days after discontinuation of lenalidomide

          -  Willing to provide research samples according to the test schedule

          -  No uncontrolled infection

          -  No NYHA classification III or IV heart disease

          -  No unstable angina (i.e., anginal symptoms at rest), new-onset angina (i.e., began
             within the past 3 months), or myocardial infarction within the past 6 months

          -  No uncontrolled hypertension, defined as systolic blood pressure &gt; 150 mm Hg or
             diastolic pressure &gt; 90 mm Hg, despite optimal medical management

          -  No thrombotic or embolic events within the past 6 months, including cerebrovascular
             accidents and transient ischemic attacks

          -  More than 4 weeks since prior pulmonary hemorrhage or other bleeding event &gt; grade 2

          -  No serious nonhealing wound or ulcer

          -  More than 4 weeks since prior significant traumatic injury

          -  No known positivity for HIV infection or infectious hepatitis, type A, B, or C

          -  No known hypersensitivity to thalidomide or lenalidomide

          -  No prior development of erythema nodosum if characterized by a desquamating rash while
             taking thalidomide or similar drugs

          -  Able to take aspirin (325 mg) daily as prophylactic anticoagulation

        PRIOR CONCURRENT THERAPY:

          -  Recovered from prior chemotherapy, regardless of interval since last treatment

          -  Prior lenalidomide therapy allowed

          -  More than 4 weeks since prior experimental therapy

          -  More than 4 weeks since prior major surgery or open biopsy

          -  No concurrent enrollment in any other study involving a pharmacologic agent or
             investigative therapy (i.e., drug, biologic, immunotherapy approaches, gene therapy)
             whether for symptom control or therapeutic intent

          -  No other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary
             therapy considered investigational

          -  No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (i.e., phenytoin,
             carbamazepine, and phenobarbital), rifampin, or Hypericum perforatum (St. John wort)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaji K. Kumar, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2008</study_first_submitted>
  <study_first_submitted_qc>May 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2008</study_first_posted>
  <results_first_submitted>November 23, 2011</results_first_submitted>
  <results_first_submitted_qc>November 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 26, 2011</results_first_posted>
  <last_update_submitted>March 7, 2012</last_update_submitted>
  <last_update_submitted_qc>March 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Thirteen (13) participants were recruited at Mayo Clinic between August 2008 and March 2010.</recruitment_details>
      <pre_assignment_details>This was a phase I/II trial. A total of 13 participants were accrued, all to the phase I portion. This trial was terminated due to study design and toxicity during the phase I; therefore, the phase II portion will never open. No results from the phase II portion are available.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sorafenib + Lenalidomide + Dexamethasone</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sorafenib + Lenalidomide + Dexamethasone</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" lower_limit="42" upper_limit="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Lenalidomide</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior Transplant</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Grade 3 and 4 Adverse Event (Phase I)</title>
        <description>Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.
Description of Grades:
Grade 1: Mild Grade 2: Moderate Grade 3: Severe Grade 4: Life-threatening Grade 5: Death</description>
        <time_frame>up to 3 years</time_frame>
        <population>One participant refused further treatment prior to being assessed for adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib + Lenalidomide + Dexamethasone</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Grade 3 and 4 Adverse Event (Phase I)</title>
          <description>Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.
Description of Grades:
Grade 1: Mild Grade 2: Moderate Grade 3: Severe Grade 4: Life-threatening Grade 5: Death</description>
          <population>One participant refused further treatment prior to being assessed for adverse events.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Achieve a Confirmed Response (Partial Response [PR], Very Good PR [VGPR], Complete Response [CR], or Stringent CR [sCR]) (Phase II)</title>
        <description>Response that was confirmed on 2 consecutive evaluations during treatment
CR: Complete disappearance of M-protein from serum &amp; urine on immunofixation, &lt;5% plasma cells in bone marrow (BM)
sCR: CR plus normal FLC ratio &amp; absence of clonal cells in BM
VGPR: &gt;=90% reduction in serum M-component; Urine M-Component &lt;100 mg per 24 hours; &lt;=5% plasma cells in BM
PR: &gt;= 50% reduction in serum M-Component and/or Urine M-Component &gt;= 90% reduction or &lt;200 mg per 24 hours; or &gt;= 50% decrease in difference between involved and uninvolved FLC levels</description>
        <time_frame>Duration on Treatment (up to 3 years)</time_frame>
        <population>No participants proceeded to Phase II for evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib + Lenalidomide + Dexamethasone</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieve a Confirmed Response (Partial Response [PR], Very Good PR [VGPR], Complete Response [CR], or Stringent CR [sCR]) (Phase II)</title>
          <description>Response that was confirmed on 2 consecutive evaluations during treatment
CR: Complete disappearance of M-protein from serum &amp; urine on immunofixation, &lt;5% plasma cells in bone marrow (BM)
sCR: CR plus normal FLC ratio &amp; absence of clonal cells in BM
VGPR: &gt;=90% reduction in serum M-component; Urine M-Component &lt;100 mg per 24 hours; &lt;=5% plasma cells in BM
PR: &gt;= 50% reduction in serum M-Component and/or Urine M-Component &gt;= 90% reduction or &lt;200 mg per 24 hours; or &gt;= 50% decrease in difference between involved and uninvolved FLC levels</description>
          <population>No participants proceeded to Phase II for evaluation.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (Phase II)</title>
        <description>Overall Survival (OS) was defined as the time from registration to death of any cause. Participants were followed for a maximum of 2 years from registration. The median OS with 95%CI was estimated using the Kaplan Meier method</description>
        <time_frame>From registration to death (up to 3 years)</time_frame>
        <population>No participants proceeded to Phase II for evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib + Lenalidomide + Dexamethasone</title>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (Phase II)</title>
          <description>Overall Survival (OS) was defined as the time from registration to death of any cause. Participants were followed for a maximum of 2 years from registration. The median OS with 95%CI was estimated using the Kaplan Meier method</description>
          <population>No participants proceeded to Phase II for evaluation.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression (Phase II)</title>
        <description>Time to disease progression (TTP) was defined as the time from registration to progression. The median TTP with 95%CI was estimated using the Kaplan Meier method.
Progression was defined as any one or more of the following:
An increase of 25% from lowest confirmed response in:
Serum M-component (absolute increase &gt;= 0.5g/dl)
Urine M-component (absolute increase &gt;= 200mg/24hour
Difference between involved and uninvolved Free Light Chain levels (absolute increase &gt;= 10mg/dl
Bone marrow plasma cell percentage (absolute increase of &gt;=10%)</description>
        <time_frame>From registration to progression (up to 3 years)</time_frame>
        <population>No participants proceeded to Phase II for evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib + Lenalidomide + Dexamethasone</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression (Phase II)</title>
          <description>Time to disease progression (TTP) was defined as the time from registration to progression. The median TTP with 95%CI was estimated using the Kaplan Meier method.
Progression was defined as any one or more of the following:
An increase of 25% from lowest confirmed response in:
Serum M-component (absolute increase &gt;= 0.5g/dl)
Urine M-component (absolute increase &gt;= 200mg/24hour
Difference between involved and uninvolved Free Light Chain levels (absolute increase &gt;= 10mg/dl
Bone marrow plasma cell percentage (absolute increase of &gt;=10%)</description>
          <population>No participants proceeded to Phase II for evaluation.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Microvessel Density From Baseline to Post-treatment and Correlation With &gt; Clinical Outcomes (Phase II)</title>
        <time_frame>Pre and Post treatment (up to 3 years)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Apoptosis Rate From Baseline to Post-treatment and Correlation With &gt; Clinical Outcomes (Phase II)</title>
        <time_frame>Pre and Post treatment (up to 3 years)</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Cell Gene Expression Profiles and Correlation With &gt; Clinical Outcomes</title>
        <time_frame>Post treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Stained Circulating Endothelial Cells and Endothelial Progenitor Cells and Correlation With Clinical Outcomes (Phase II</title>
        <time_frame>Post treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in VEGF Expression Levels and Correlation With Clinical Outcomes (Phase II)</title>
        <time_frame>Post treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sorafenib + Lenalidomide + Dexamethasone</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="53" subjects_affected="11" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oral cavity Mucositis/stomatitis (clinical exam)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="63" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Bilirubin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="64" subjects_affected="10" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="62" subjects_affected="10" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="74" subjects_affected="10" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="7" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pulmonary</sub_title>
                <counts group_id="E1" events="9" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hand-foot skin reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="13" subjects_affected="4" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Shaji Kumar</name_or_title>
      <organization>Mayo Clinic</organization>
      <email>kumar.shaji@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

